ValuEngine cut shares of Corvus Pharmaceuticals (NASDAQ:CRVS) from a sell rating to a strong sell rating in a research report sent to investors on Friday morning.
Separately, Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company has a consensus rating of Hold and an average target price of $20.25.
Corvus Pharmaceuticals (CRVS) opened at $8.03 on Friday. The company has a market cap of $168.96, a price-to-earnings ratio of -2.99 and a beta of -2.39. Corvus Pharmaceuticals has a 1 year low of $7.81 and a 1 year high of $22.14.
In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 10,000 shares of the stock in a transaction dated Monday, November 20th. The shares were bought at an average cost of $10.79 per share, with a total value of $107,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 46.40% of the company’s stock.
Large investors have recently modified their holdings of the company. New York State Common Retirement Fund grew its position in shares of Corvus Pharmaceuticals by 2,269.1% in the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after purchasing an additional 9,099 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Corvus Pharmaceuticals in the fourth quarter valued at about $150,000. Alliancebernstein L.P. acquired a new stake in shares of Corvus Pharmaceuticals in the second quarter valued at about $175,000. California State Teachers Retirement System grew its position in shares of Corvus Pharmaceuticals by 121.2% in the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock valued at $181,000 after purchasing an additional 8,200 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in shares of Corvus Pharmaceuticals by 338.4% in the second quarter. Teachers Advisors LLC now owns 15,568 shares of the company’s stock valued at $188,000 after purchasing an additional 12,017 shares during the last quarter. 81.42% of the stock is currently owned by institutional investors.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.